Company Background

We are a Minnesota-based, privately held company engaged in the development of an innovative, hands-free sensoring/monitoring system to measure partial pressure of carbon dioxide (“pCO2”) in the oral mucosal tissue. The device is called the MicroTrend™ System.


Our pioneering leadership in the field dates back many years, with a variety of successful advancements and important breakthroughs along the way—including development of the first and only FDA cleared-to-market device measuring pCO2 in oral mucosal tissue.

Early 2000s

The Weil Institute of Critical Care Medicine (WICCM) obtains a number of significant patents from its groundbreaking, and clinically corroborated, research on the connection between tissue hypoperfusion and CO2 levels in bodily mucosal tissue.



ExoStat’s predecessor, Optical Sensors, Inc., enters a patent agreement with WICCM and develops the first and only cleared-to-market technology to measure pCO2 in sublingual tissue.



ExoStat is spun off from its parent company in order to focus efforts and resources on developing an improved version of the technology.



ExoStat enters into a long-term patent licensing and technology agreement with SensoCure, AS, a Norwegian sensor development company that holds several key sensor technology patents



Major, ongoing technological advances have been achieved, and ExoStat is nearing the final stages of product development.


The new MicroTrendTM System will feature hands-free monitoring capabilities that will provide caregivers easy access to previously unavailable information about tissue condition.

Contact Us

Ischemia therefore is not only an oxygen deficit but also a CO2 excess, which is a universal phenomenon of tissue failure (tissue hypoperfusion).”


Dr. Max Harry Weil


founder of the Weil Institute and one of the first researchers of oral pCO2